Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 11, 2023 05:00 ET | Source: Paradigm Biopharmaceuticals

Australia’s Paradigm Biopharmaceuticals says phase 2 trial in osteoarthritis shows signs of disease modification at 6-month follow-up

MELBOURNE, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Australia’s Paradigm Biopharmaceuticals Ltd (ASX:PAR) says analysis of six-month trial data shows injectable pentosan polysulfate sodium...